On October 25, 2021 Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, reported it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in Washington, D.C., from November 10-14, 2021 (Press release, Palleon Pharmaceuticals, OCT 25, 2021, View Source [SID1234591914]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Palleon’s poster highlights recent preclinical data from in vitro and in vivo studies of the company’s most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase). E-602 is part of the company’s novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.
In addition to the poster presentation, Palleon will be hosting a hybrid (live and virtual) scientific symposium at SITC (Free SITC Whitepaper) on November 11th featuring Palleon Scientific Co-Founder Carolyn Bertozzi, Ph.D., Scientific Advisor James Paulson, Ph.D., and Chief Medical Officer David Feltquate, M.D., Ph.D. The session will review the most recent state of the science of sialoglycan-mediated immune regulation and its potential relevance for immuno-oncology therapeutics. To learn more and register to attend, visit this link.
"We’re looking forward to sharing more about the development of our EAGLE platform and the lead program E-602, which we believe is a uniquely powerful way to reverse the immunosuppressive effect of cell-surface sialoglycans," said Li Peng, Ph.D., Chief Scientific Officer. "These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology."
Details of the poster presentation are as follows:
Title: Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer
Number: 843
Presenter: Li Peng, Ph.D., Chief Scientific Officer
Details of the symposium are as follows:
Title: Sialoglycan-Mediated Immune Regulation: Glycobiology Meets Immuno-Oncology
Timing: November 11, 2021, 6:30 p.m. – 8:00 p.m. EST
Registration Link
Presenters:
Carolyn Bertozzi, Ph.D.
Anne T. and Robert M. Bass Professor of Chemistry at Stanford University; Baker Family Director of Stanford ChEM-H; Scientific Co-Founder, Palleon Pharmaceuticals
James Paulson, Ph.D.
Cecil H. and Ida M. Green Professor and Co-Chair, Department of Molecular Medicine, and Professor, Department of Immunology and Microbiology, Scripps Research Institute; Scientific Advisor, Palleon Pharmaceuticals
David Feltquate, M.D., Ph.D.
Chief Medical Officer, Palleon Pharmaceuticals